Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD

Blood (2019) 134 (Supplement_1): 3928.

https://doi.org/10.1182/blood-2019-125327

Published: 2019

Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3916.

https://doi.org/10.1182/blood-2019-124034

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 5566.

https://doi.org/10.1182/blood-2019-129002

Published: 2019

Journal Articles

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Hong-Hui Huang, PhD MD, Jian Hou, PhD MD, Yang-Ming Zhang, PhD, Yu-Bo Zhou, PhD, Li Jia, PhD, Fa-Jun Nan, PhD

Blood (2019) 134 (Supplement_1): 5591.

https://doi.org/10.1182/blood-2019-129683

Published: 2019

Journal Articles

Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction Therapy Prior to Autologous Peripheral Blood Stem Cell Transplantation in Young Patients Diagnosed of Multiple Myeloma. a Retrospective Analysis from Two Centers

David Jiménez Ruiz De La Torre, MD, Gladys Ibarra, MD, Maite Encuentra, Laura Abril, MD, Albert Oriol, MD, Josep-Maria Ribera, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 5568.

https://doi.org/10.1182/blood-2019-130107

Published: 2019

Journal Articles

Bortezomib: Once-Weekly 1.6mg/m 2 Maybe a Better Choice Compared with Twice-Weekly 1.3mg/m 2 in Newly Dignosed Multiple Myeloma

Yubin Li, Fangfang Li, Wangshan Song, Zhumei Zhan, Xiangxin Li, Lingling Wang, Fanglin Li, MD, Ming Hou, MD PhD, Hao Li, MD, Luqun Wang, MD PhD

Blood (2019) 134 (Supplement_1): 5558.

https://doi.org/10.1182/blood-2019-125714

Published: 2019

Journal Articles

A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells

Min Lu, PhD, Lijuan Xia, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 4201.

https://doi.org/10.1182/blood-2019-129017

Published: 2019

Journal Articles

Oral idasanutlin in patients with polycythemia vera

John Mascarenhas, Min Lu, Heidi Kosiorek, Elizabeth Virtgaym, Lijuan Xia, Lonette Sandy, Ruben Mesa, Bruce Petersen, Noushin Farnoud, Vesna Najfeld, Raajit Rampal, Amylou Dueck, Ronald Hoffman

Blood (2019) 134 (6): 525–533.

https://doi.org/10.1182/blood.2018893545

Published: 2019

Includes: Supplemental data

Journal Articles

Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant

Blood (2018) 132 (Supplement 1): 608.

https://doi.org/10.1182/blood-2018-99-110857

Published: 2018

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Thomas Michael Schroeder, MD PhD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Christoph Groth, MD, Christoph Scheid, MD, Udo Holtick, MD PhD, Stefan A Klein, MD, Dietrich W. Beelen, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, MD, Guido Kobbe

Blood (2018) 132 (Supplement 1): 703.

https://doi.org/10.1182/blood-2018-99-113776

Published: 2018

Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Blood (2018) 132 (Supplement 1): 253.

https://doi.org/10.1182/blood-2018-99-111203

Published: 2018

Journal Articles

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Alessandro Re, MD, Nicola Bianchetti, Chiara Cattaneo, MD, Salvatore Casari, MD, Chiara Pagani, MD, Annalisa Peli, MD, Emanuele Focà, MD, Pierino ferremi Leali, MD, Camillo Almici, MD, Francesco Castelli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2018-99-116816

Published: 2018

Journal Articles

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Annamaria Brioli, MD, Kirsi Manz, Mathias Hänel, MD, Markus Pfirrmann, PhD, Andreas Christoph Schwarzer, MD, Marie von Lilienfeld-Toal, MD, Gabriele Prange-Krex, Christian Fabisch, PhD, Stefan Knop, Thomas Illmer, MD, Beate Krammer-Steiner, Andreas Hochhaus, MD, Lars-Olof Mügge, MD

Blood (2018) 132 (Supplement 1): 2016.

https://doi.org/10.1182/blood-2018-99-115964

Published: 2018

Journal Articles

Association of Sarcopenia with Toxicities and Survival after Autologous Hematopoietic Stem Cell Transplantation for Adults with Lymphomas

Abel Costa Neto, MD, Bruna Del Guerra Carvalho Moraes, Ilanna Marques Gomes Rocha, Felipe Acquesta Bezerra, MD, Galtieri Otavio Cunha Medeiros, Lucas Bassolli Oliveira Alves, Renata Ariza Marques Rossetti, PhD, Ana Paula Trussardi Fayh, PhD, Livia Caroline Barbosa Mariano, MD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 2158.

https://doi.org/10.1182/blood-2018-99-117717

Published: 2018

Journal Articles

Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma

Nicole Pearl, PharmD, Andrew Lin, PharmD, BCOP, Patrick Hilden, MS, Larry W Buie, PharmD, BCOP, FASHP, Kevin Robinson, Molly Maloy, MS, Gunjan L. Shah, MD

Blood (2018) 132 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2018-99-119554

Published: 2018

Journal Articles

Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes

Najla H El Jurdi, MD, Ali Filali, PhD, Iman Salem, MD, Mauricio Retuerto, MS, Nina Dambrosio, CNP, Hillard M Lazarus, MD, Richard Creger, PharmD, Paolo F Caimi, MD, Brenda Cooper, MD, Ben Tomlinson, MD, Leland Metheny, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Rafick-Pierre Sekaly, PhD, Mahmoud Ghannoum, PhD, Marcos de Lima, MD

Blood (2018) 132 (Supplement 1): 5754.

https://doi.org/10.1182/blood-2018-99-120125

Published: 2018

Journal Articles

Altering Glycosphingolipid Composition to Improve Multiple Myeloma Bone Complication

Houfu Leng, MSc, DPhil, MBBS, BSc, Adel Ersek, PhD, Emma Morris, DPhil, Beatriz Gamez Molina, PhD, Claire M. Edwards, PhD, Nicole Horwood, PhD

Blood (2018) 132 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2018-99-112237

Published: 2018

Journal Articles

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

Blood (2017) 130 (Supplement 1): 898.

https://doi.org/10.1182/blood.V130.Suppl_1.898.898

Published: 2017

Journal Articles

A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014)

Andrea Biondi, MD, Virginie Gandemer, MDPhD, Myriam Campbell, MD, Anders Castor, MD PhD, Rob Pieters, MD PhD, Paola De Lorenzo, PhD, Veronica Leoni, MD, Jan Stary, Gabriele Escherich, MD, Chi Kong Li, MD, Giovanni Cazzaniga, PhD, Helene Cave, PharmD, PhD, Silja Roettgers, PhD, Valentino Conter, MD, Vaskar Saha, MD PhD, Martin Schrappe, MD PhD, Maria Grazia Valsecchi, PhD

Blood (2017) 130 (Supplement 1): 97.

https://doi.org/10.1182/blood.V130.Suppl_1.97.97

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction Therapy Prior to Autologous Peripheral Blood Stem Cell Transplantation in Young Patients Diagnosed of Multiple Myeloma. a Retrospective Analysis from Two Centers

Bortezomib: Once-Weekly 1.6mg/m 2 Maybe a Better Choice Compared with Twice-Weekly 1.3mg/m 2 in Newly Dignosed Multiple Myeloma

A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells

Oral idasanutlin in patients with polycythemia vera

Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Induction with Bortezomib Melphalan and Prednisolon (VMP) Is Associated with Unexpectedly High Discontinuation Rate in Elderly Multiple Myeloma Patients: First Analysis of the German Maintenance (GERMAIN) Trial

Association of Sarcopenia with Toxicities and Survival after Autologous Hematopoietic Stem Cell Transplantation for Adults with Lymphomas

Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma

Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes

Altering Glycosphingolipid Composition to Improve Multiple Myeloma Bone Complication

Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort

A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only